On Mar. 31, 2020, Emergent BioSolutions announced an agreement with Novavax whereby Emergent will provide molecule-to-market contract development and manufacturing services to produce Novavax’s NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M- adjuvant.

Under the terms of the agreement, Emergent provided drug substance manufacturing services, including technology transfer and process validation and performance qualification to pave the way for commercial manufacturing. This work was conducted at Emergent’s Baltimore Bayview location, which is designated by the U.S. Department of Health and Human Services (HHS) as a Center for Innovation in Advanced Development and Manufacturing (CIADM), and where the COVID-19 experimental vaccine candidate of Novavax was also produced.